Halozyme Completes Acquisition of Elektrofi for Up to $900 Million

Reuters11-18

Halozyme Completes Acquisition of Elektrofi for Up to $900 Million

Halozyme Therapeutics has completed its acquisition of Elektrofi, a biopharmaceutical company specializing in ultra-high concentration microparticle formulation technology for biologics, known as Hypercon. The deal includes an upfront payment of $750 million and up to three $50 million milestone payments tied to regulatory approvals, for a total potential consideration of $900 million. Halozyme expects royalty revenue contributions from the acquired business to begin as early as 2030. Two of Elektrofi's partner programs are projected to enter clinical development by the end of 2026 or sooner, with up to $275 million in potential development and commercial milestone payments anticipated from these programs. The transaction is expected to result in less than 5% dilution to non-GAAP diluted EPS over the medium term, excluding potential milestone payments, and the company anticipates approximately $55 million in incremental operating expenses for the full year 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA27413) on November 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584958109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584958109","market":"us","top_or_hot":-1,"title":"Halozyme Completes Acquisition of Elektrofi for Up to $900 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Halozyme Completes Acquisition of Elektrofi for Up to $900 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has completed its acquisition of Elektrofi, a biopharmaceutical company specializing in ultra-high concentration microparticle formulation technology for biologics, known as Hypercon. The deal includes an upfront payment of $750 million and up to three $50 million milestone payments tied to regulatory approvals, for a total potential consideration of $900 million. Halozyme expects royalty revenue contributions from the acquired business to begin as early as 2030. Two of Elektrofi's partner programs are projected to enter clinical development by the end of 2026 or sooner, with up to $275 million in potential development and commercial milestone payments anticipated from these programs. The transaction is expected to result in less than 5% dilution to non-GAAP diluted EPS over the medium term, excluding potential milestone payments, and the company anticipates approximately $55 million in incremental operating expenses for the full year 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA27413) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme Completes Acquisition of Elektrofi for Up to $900 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme Completes Acquisition of Elektrofi for Up to $900 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-18 21:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Halozyme Completes Acquisition of Elektrofi for Up to $900 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has completed its acquisition of Elektrofi, a biopharmaceutical company specializing in ultra-high concentration microparticle formulation technology for biologics, known as Hypercon. The deal includes an upfront payment of $750 million and up to three $50 million milestone payments tied to regulatory approvals, for a total potential consideration of $900 million. Halozyme expects royalty revenue contributions from the acquired business to begin as early as 2030. Two of Elektrofi's partner programs are projected to enter clinical development by the end of 2026 or sooner, with up to $275 million in potential development and commercial milestone payments anticipated from these programs. The transaction is expected to result in less than 5% dilution to non-GAAP diluted EPS over the medium term, excluding potential milestone payments, and the company anticipates approximately $55 million in incremental operating expenses for the full year 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA27413) on November 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL8b1ND4:1","article_id":"2584958109","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584958109","pubTimestamp":1763473820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Halozyme Therapeutics has completed its acquisition of Elektrofi, a biopharmaceutical company specializing in ultra-high concentration microparticle formulation technology for biologics, known as Hypercon. The deal includes an upfront payment of $750 million and up to three $50 million milestone payments tied to regulatory approvals, for a total potential consideration of $900 million. Halozyme expects royalty revenue contributions from the acquired business to begin as early as 2030. Two of Elektrofi's partner programs are projected to enter clinical development by the end of 2026 or sooner, with up to $275 million in potential development and commercial milestone payments anticipated from these programs. The transaction is expected to result in less than 5% dilution to non-GAAP diluted EPS over the medium term, excluding potential milestone payments, and the company anticipates approximately $55 million in incremental operating expenses for the full year 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","HALO":"奥洛兹美医疗","BK4139":"生物科技"},"translate_title":"Halozyme以高达9亿美元完成对Elektrofi的收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"Halozyme Completes Acquisition of Elektrofi for Up to $900 Million\n    \n\n        Halozyme Therapeutics has completed its acquisition of Elektrofi, a biopharmaceutical company specializing in ultra-high concentration microparticle formulation technology for biologics, known as Hypercon. The deal includes an upfront payment of $750 million and up to three $50 million milestone payments tied to regulatory approvals, for a total potential consideration of $900 million. Halozyme expects royalty revenue contributions from the acquired business to begin as early as 2030. Two of Elektrofi's partner programs are projected to enter clinical development by the end of 2026 or sooner, with up to $275 million in potential development and commercial milestone payments anticipated from these programs. The transaction is expected to result in less than 5% dilution to non-GAAP diluted EPS over the medium term, excluding potential milestone payments, and the company anticipates approximately $55 million in incremental operating expenses for the full year 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA27413) on November 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584958109","isCrawlerRequest":true}